Xconomy
JULY 22, 2016
It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. And in other Amgen news, the Thousand Oaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab.
Xconomy
AUGUST 26, 2016
—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017.
Xconomy
AUGUST 5, 2016
—Gene therapy news: After investing in Bamboo Therapeutics and its Duchenne muscular dystrophy treatment earlier this year, Pfizer bought the Chapel Hill, NC-based biotech outright on Monday for $150 million up front , with potentially another $495 million later. . Regeneron is paying $25 million upfront.
Expert insights. Personalized for you.
40 
Let's personalize your content